RxDoctor Payments Data

Sarah Disanto

Family · Geneva, NYNPI 1043695778

Payments from drug & device makers

$1,320in general payments, 2019–2025

Across 66 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$351
  • AbbVie$255
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$138
  • Straumann USA LLC$119
  • Ardelyx, Inc.$69
  • Takeda Pharmaceuticals U.S.A., Inc.$67
  • plus $321 from 12 others

What the payments were for

  • Food & beverage$1,23093%
  • Education$907%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,320 in reported general payments places this provider in the 75th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$23,184
Medicare patients
238
Services billed
308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase13$35,582
LinzessLinaclotide31$31,774
Dexlansoprazole DrDexlansoprazole39$9,512
DexilantDexlansoprazole13$8,301
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates126$7,624
Mesalamine17$7,143
Budesonide DrBudesonide24$3,787
Omeprazole242$3,719
ClenpiqSod Picosulf/Mag Ox/Citric Ac19$3,293
Pantoprazole Sodium206$2,064
Famotidine145$1,965
Esomeprazole Magnesium47$1,888
Rabeprazole Sodium30$1,155
Dicyclomine Hcl36$1,041
Lansoprazole12$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$255$67,35644 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$67$8,30113 claims
Ferring Pharmaceuticals Inc.Clenpiq$40$3,29319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,883 family providers in New York.

Other family in Geneva

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →